Hansen, Troels Krarup

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 351

Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The adjunct two randomized trial

Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 262

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial

von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology

Diabetes and associated disordersPancreatic function and diabetes

Cited by 186

Ghrelin Infusion in Humans Induces Acute Insulin Resistance and Lipolysis Independent of Growth Hormone Signaling

Vestergaard, E. T., Gormsen, L. C., Jessen, N., Lund, S., Hansen, T. K., Moller, N., & Jorgensen, J. O. L. (2008) · Diabetes

Regulation of Appetite and ObesityGrowth Hormone and Insulin-like Growth Factors

Cited by 156

Early‐onset type 2 diabetes: Age gradient in clinical and behavioural risk factors in 5115 persons with newly diagnosed type 2 diabetes—Results from the DD2 study

Bo, A., Thomsen, R. W., Nielsen, J. S., Nicolaisen, S. K., Beck‐Nielsen, H., Rungby, J., Sørensen, H. T., Hansen, T. K., Søndergaard, J., Friborg, S., et al. (2018) · Diabetes/Metabolism Research and Reviews

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 62

Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: A prospective study

Fadini, G. P., Feher, M., Hansen, T. K., de Valk, H. W., Koefoed, M. M., Wolden, M., Zimmermann, E., & Jendle, J. (2019) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 27

Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial

Pedersen‐Bjergaard, U., Agesen, R. M., Brøsen, J. M. B., Alibegovic, A. C., Andersen, H. U., Beck‐Nielsen, H., Gustenhoff, P., Hansen, T. K., Hedetoft, C., Jensen, T. J., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 16